[Vaccinations in recurrent urinary tract infections--an observation study relating to health economy].
OBJECTIVE
Urinary tract infection (UTI) is one of the most common bacterial infections in women. Despite the need for therapy alter-natives only the conventional treatment using antibiotics is investigated in the literature. A vaccination, however, can be a useful medical and economic alternative for the treatment of recurrent urinary tract infections.


METHODS
An open, prospective, not-randomised, multicentric observation study was carried out to determine the costs and effects of a vaccination in 842 patients with recurrent urinary tract infections. The data for efficacy, safety and costs of recurrent urinary tract infections were collected via patient documentation and a standardised documentation of the physicians.


RESULTS
The efficacy was rated as good to very good by 82.7 % of the physicians and 82.1 % of the patients. The values for safety show even better results. They were rated as good to very good by 92.4 % of the physicians and 90.9 % of the patients. The total costs amounted to 433 euro per patient in the six months before vaccination and decreased significantly to 238 euro in the six months after vaccination (p < 0.0001).


CONCLUSIONS
The results of this observation study show a clinically relevant reduction of recurrent urinary tract infections with acceptable side effects in the six months after vaccination. As the treatment costs are reduced from a mean of 238 euro to 91 euro per patient. The healthcare insurances can also benefit from the vaccination against recurrent urinary tract infections.
Lenk
Volker Severin
VS
Privatpraxis für Urologie und Andrologie, Gesundheitszentrum Blütenhof-Berlin, Berlin. info@urologie-lenk.de
Dorsch
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007117:Immunization, Secondary / Q000191:economics; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000191:economics* / Q000382:microbiology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics*; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000191:economics*; D055815:Young Adult
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated